Drug Profile
Research programme: CD95 ligand inhibitors - Apogenix/German Cancer Research Center
Alternative Names: APG103Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Apogenix
- Developer Apogenix; German Cancer Research Center
- Class Proteins
- Mechanism of Action CD95 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany (Parenteral)
- 29 Jul 2009 Preclinical trials in Inflammation in Germany (Parenteral)